Recent preclinical research has demonstrated that pharmacological inhibition of IDO1 enzymatic activity or genetic deletion of IDO1 abrogates inflammation-dependent behavioral changes that model depression. The gene discussed is IDO1; the disease is depressive symptom measurement.